From Discovery to Clinical Insights – the power of integrating proteomics and genomics data
The value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing
From Discovery to Clinical Insights – the power of integrating proteomics and genomics data
Recent advancements in the field of proteomics have revolutionized the field of multiomics. The SomaScan® Assay from SomaLogic is the only proteomic technology capable of high-plex (measuring over half of the human proteome – 11,000 proteins), high-throughput (rapid processing time and data turnaround), and high sensitivity (measuring both high- and low-abundant proteins) from a single biological sample. Please join us to learn the value of adding high-plex proteomics to existing genomics data and how proteogenomic approaches accelerate drug target discovery and repurposing.
Maik Pietzner, PhD
Berlin Institute of Health at Charité
Universitätsmedizin Berlin, Berlin, Germany
Maik co-leads the group for Computational Medicine at the Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Germany and holds a chair for Health Data Modelling at the Precision Healthcare University Research Institute (PHURI), Queen Mary University of London, UK. He has co-led multiple efforts to associate human genetic variation at scale with intermediate molecular layers, such as proteomics and metabolomics, among various population-based studies that have identified novel pathophysiological pathways and possible treatment targets. His work on protein quantitative trait loci is spearheading the field and he has recently embarked on the integration of electronic health records to systematically augment the space of diagnosis and diseases amendable to in silico prioritisation of novel treatment targets, drug repurposing, or de-risking anchored on rare and common variation in the human genome. His influence on the field is demonstrated by an outstanding track record with publications in Science and the Nature family. Maik obtained his training and PhD in biomathematics at the University of Greifswald graduating with distinction.
From Discovery to Clinical Insights – the power of integrating proteomics and genomics data
A presentation by Maik Pietzner, PhD
More webinars
WebinarProteomics in Clinical Trials: Lessons from Semaglutide Treatment in Individuals with Obesity
Advancements in proteomic profiling have opened new avenues for understanding the complex mechanisms underlying obesity and its comorbidities. By measuring thousands of proteins at once, researchers gain a comprehensive view of an individual’s metabolic health, revealing subclinical processes and pinpointing potential therapeutic targets.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.